Evidence map›Paper›PMID 38975609›Full record

ReviewAsia-Pacific journal of oncology nursing2024

Nursing care for chimeric antigen receptor T cell therapy survivors: A literature review.

Mercedes Montoro-Lorite, Cristina Moreno, Carla Ramos, María Teresa Solano, Silvia Lahoz, Carolina Bonilla-Serrano, Ariadna Domènech, Pilar Ayora

Abstract readReview
In one paragraph

Review in Asia-Pacific journal of oncology nursing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mercedes Montoro-LoriteInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
Cristina MorenoInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
Carla RamosInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
María Teresa SolanoInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
Silvia LahozInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
Carolina Bonilla-SerranoInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
Ariadna DomènechInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
Pilar AyoraInstitute of Cancer and Blood Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy that involves genetically modifying the patient's own T cells to express a chimeric antigen receptor, enabling them to recognize and destroy cancer cells. This treatment has revolutionized the prognosis and management of hematological malignancies, leading to a significant increase in long-term survivors. However, there is limited evidence regarding late sequelae and post-treatment care due to the recent emergence of this therapy. The rapid advancement of CAR-T therapies has created opportunities for advanced practice nurses to play a crucial role in coordinating care, providing education, and ensuring the ongoing well-being of survivors. This article provides an overview of the physical, psychosocial, and financial challenges faced by long-term survivors of CAR-T therapy and proposes a comprehensive nursing care plan to address these issues.

Indexed as

Advance practice nursingCancer careCancer survivorsCAR T-cell therapyNurses' practice patternsNurse's role

Identifiers

PMID38975609
PMCPMC11225008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.